Show simple item record

dc.contributor.authorIskandar, K.
dc.contributor.authorRezlan, M.
dc.contributor.authorYadav, S.
dc.contributor.authorFoo, C.
dc.contributor.authorSethi, G.
dc.contributor.authorQiang, Y.
dc.contributor.authorBellot, G.
dc.contributor.authorPervaiz, Shazib
dc.identifier.citationIskandar, K. and Rezlan, M. and Yadav, S. and Foo, C. and Sethi, G. and Qiang, Y. and Bellot, G. et al. 2016. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production. Antioxidants and Redox Signaling. 24 (14): pp. 781-794.

© 2016 Mary Ann Liebert, Inc. We recently reported the death-inducing activity of a small-molecule compound, C1, which triggered reactive oxygen species (ROS)-dependent autophagy-associated apoptosis in a variety of human cancer cell lines. In this study, we examine the ability of the compound to specifically target cancer cells harboring mutant KRAS with minimal activity against wild-type (WT) RAS-expressing cells. Results: HCT116 cells expressing mutated KRAS are susceptible, while the WT-expressing HT29 cells are resistant. Interestingly, C1 triggers activation of mutant RAS, which results in the downstream phosphorylation and activation of AKT/PKB. Gene knockdown of KRAS or AKT or their pharmacological inhibition resulted in the abrogation of C1-induced ROS production and rescued tumor colony-forming ability. We also made use of HCT116 mutant KRAS knockout (KO) cells, which express only a single WT KRAS allele. Exposure of KO cells to C1 failed to increase mitochondrial ROS and cell death, unlike the parental cells harboring mutant KRAS. Similarly, mutant KRAS-transformed prostate epithelial cells (RWPE-1-RAS) were more sensitive to the ROS-producing and death-inducing effects of C1 than the vector only expressing RWPE-1 cells. An in vivo model of xenograft tumors generated with HCT116 KRASWT/MUT or KRASWT/- cells showed the efficacy of C1 treatment and its ability to affect the relative mitotic index in tumors harboring KRAS mutant. Innovation and Conclusion: These data indicate a synthetic lethal effect against cells carrying mutant KRAS, which could have therapeutic implications given the paucity of KRAS-specific chemotherapeutic strategies.

dc.publisherMary Ann Liebert, Inc. Publishers
dc.titleSynthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production
dc.typeJournal Article
dcterms.source.titleAntioxidants and Redox Signaling
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusFulltext not available

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record